Epilepsia
-
Spike and slow waves consist of a "spike" including high-frequency oscillations (HFOs), which are linked to epileptogenicity and a "post-spike slow wave (PSS)" related to inhibitory activity. The aim of this study was to elucidate the spatiotemporal relationship between spike-related HFOs and PSS in patients with focal cortical dysplasia (FCD) type II. ⋯ Relative power reduction of PSS to spike-related HFOs in SOZ is relevant for seizure initiation. Our analysis will contribute to future studies of seizure prediction and distinction between pathologic and physiologic HFOs. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.
-
We describe a novel method to spatially map interictal epileptiform discharges (IEDs) through voxel-wise functional connectivity analysis of the functional magnetic resonance imaging (fMRI) portion of simultaneous electroencephalography (EEG)-fMRI data. This method measures the local synchronicity of fMRI signals associated with IED and, in contrast to conventional methods, does not require modeling of neural activities or hemodynamic response. ⋯ We show that for focal epilepsy, voxel-wise functional connectivity analysis of EEG-fMRI data may improve IED localization and EEG concordance compared to the conventional analysis. This new analytic method may improve the robustness of interictal EEG-fMRI as a technique for mapping the epileptogenic focus, and helps study the local synchronization aspect of the epileptic network.
-
Both atopic dermatitis and epilepsy have been regarded as chronic inflammatory diseases. However, their association has yet to be investigated. ⋯ Subjects with atopic dermatitis were associated with an increased risk of developing epilepsy in later life. Further studies would be needed to investigate the underlying mechanisms.
-
Randomized Controlled Trial Multicenter Study
Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial.
To assess the efficacy and tolerability of add-on pregabalin controlled-release formulation (PGB-CR) (doses of 165 or 330 mg/day) in patients with partial-onset seizures (POS). ⋯ Results from this trial did not demonstrate that PGB-CR is effective in reducing seizure frequency below that of placebo. Both doses of PGB-CR were shown to be safe and well-tolerated.